Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.025 (-1.59%)
Spread: 0.10 (6.667%)
Open: 1.575
High: 1.575
Low: 1.55
Prev. Close: 1.575
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Aston Martin CEO ups stake; Alkemy's lithium deal

Tue, 03rd Oct 2023 17:14

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Aston Martin Lagonda Global Holdings PLC - Gaydon, England-based luxury sports car manufacturer - Chief Executive Lawrence Stroll increases stake to 26% from 23% on October 3.

----------

Edinburgh Investment Trust PLC - Edinburgh-based investment trust - Liontrust Fund Partners LLP informs company that James de Uphaugh, the company's portfolio manager, will retire in February 2024. De Uphaugh will continue to manage the portfolio until February and will then be replaced as by Imran Sattar. As part of the succession, Sattar has been appointed deputy portfolio manager, replacing Chris Field who is due to retire from Liontrust in November. Other than the change of portfolio manager, there will be no change to the two investment objectives, strategy or the portfolio's key features, company says.

----------

DWF Group PLC - Manchester, England-based legal business with operations in North America - Announces the scheme which facilitates the bid by Inflexion Private Equity Partners LLP has become effective. The entire issued share capital of DWF is now owned or controlled by Inflexion. Shares in DWF have been suspended and are expected to be cancelled on October 4. As a result of the scheme becoming effective, DWF announces that: Teresa Colaianni, Samantha Duncan, Luke Savage, Jonathan Bloomer and Chris Sullivan have resigned as non-executive directors with effect from October 3. Further, Seema Bains and Michele Cicchetti have resigned as partner directors of the board with effect from October 3.

----------

Angus Energy PLC - UK-focused oil and gas development company - Reports gas volumes produced and sold from the Saltfleetby Field equalled 7.9 million therms in aggregate for the months of July, August and September, compared to 6.8 million therms produced and sold in the second quarter of this year. Notes third quarter production equates to an average of 2.6 million therms per month, up from 2.3 million therms per month in the second quarter, and against hedged volumes of 1.5 million therms per month for the third quarter, down from 1.75 million therms per month for the second quarter. Operational efficiency was 90% for the third quarter compared to 88% operational efficiency for the second quarter. The quarter included a planned full plant shut down for four days at the end of August for safety-critical maintenance and remedial work on one of the two compressor engines on the Saltfleetby site. Further, states work on the previously announced global refinance of the company's debt is well advanced, with a new reservoir model and production forecasts in the process of being finalized for lenders.

----------

Alkemy Capital Investments PLC - London-based company focused on acquisitions in the mining and technology metals sectors - Says Tees Valley Lithium has been shortlisted by a major automotive original equipment manufacturer as the preferred European lithium refiner for a portion of its lithium supply chain after extensive due diligence. Explains Tees Valley is a wholly owned UK subsidiary. Explains the due diligence focussed on Tees Valley Lithium's ability to import a lithium sulphate from its Port Hedland facility in Western Australia and the conversion into battery grade lithium hydroxide or carbonate at an internationally competitive price. Discussions are also advancing well with third parties, including other automotive OEMs, for access to Tees Valley Lithium's multi-train facilities, company states. Further, discussions are ongoing with two major trading groups to supply technical grade carbonate from South America and elsewhere to feed directly one of the trains at Tees Valley Lithium's Wilton refinery to produce battery grade lithium products on a toll treatment basis.

----------

City of London Investment Group PLC - investor in London-listed equities - Confirms Barry Aling will be retiring as non-executive chair at the annual general meeting on October 23. Says Rian Dartnell, a current non-executive director will become chair. Further, says Ted Sevick has been promoted to chief operating officer.

----------

Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Confirms retail offer, launched on September 28, raised GBP118,337 taking total of fundraise to GBP5.1 million. The retail offer will result in the issue of a total of around 1.5 million shares.

----------

More News
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more
3 Apr 2019 10:10

Shield Therapeutics narrows losses as it advances Feraccru to market

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.

Read more
3 Apr 2019 09:56

Shield Therapeutics Cuts Loss In 2018; Licence Payment Lifts Revenue

LONDON (Alliance News) - Drug maker Shield Therapeutics PLC said Wednesday its 2018 loss narrowed significantly as revenue surged on a licence payment boost amid a year of "transition" a

Read more
14 Mar 2019 15:52

Shield Therapeutics Secures Positive Decision On Feraccru's Patent

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru

Read more
4 Mar 2019 11:26

Shield Therapeutics upbeat on latest Feraccru trial results

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.

Read more
29 Jan 2019 11:21

Shield Therapeutics Gets Positive Results From Feraccru Study

LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.Shares in the company were a

Read more
29 Jan 2019 10:02

Shield Therapeutics upbeat on results of latest Feraccru study

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on Tuesday.

Read more
24 Jan 2019 14:16

Shield Therapeutics Expects 2018 Revenue Growth On Licence Payments

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said it expects its revenue to surge in 2018 on the back of licence payments for its Feraccru capsules.The pharmaceutical has in

Read more
24 Jan 2019 10:02

Shield Therapeutics revenues surge following commercialisation deal

(Sharecast News) - Shield Therapeutics saw revenues rocket in the second half of its trading year following a commercialisation agreement with European pharmaceutical specialist Norgine.

Read more
22 Jan 2019 13:35

Shield Therapeutics Appoints Director James Karis As Chair

LONDON (Alliance News) - Shield Therapeutics PLC said Tuesday that it has promoted board member James Karis to be non-executive chair with immediate effect.Karis has served on Shield's

Read more
22 Jan 2019 09:56

Shield Therapeutics promotes Karis to chairman

(Sharecast News) - Commercial stage pharmaceutical outfit Shield Therapeutics elevated James Karis to the role of non-executive chairman on Tuesday.

Read more
13 Dec 2018 11:57

FDA gives target date for Shield's Feraccru application

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Thursday that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of 'Feraccru', under the terms of the Prescription Drug User Fee Act, would be 27 July 2019.

Read more
5 Dec 2018 13:07

Shield Therapeutics' Feraccru treatment launched in UK

(Sharecast News) - Shield Therapeutics' treatment for iron deficiency in adults, Feraccru, was launched in the UK on Wednesday by specialist pharmaceutical company Norgine.

Read more
5 Dec 2018 11:57

Shield Therapeutics Partner Norgine Launches Feraccru In UK

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.In September 2018, Shield,

Read more
24 Sep 2018 14:30

DIRECTOR DEALINGS: Shield Therapeutics Boss Sterritt Buys More Stock

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Chief Executive Carl Sterritt bought more shares in the company in a deal on Friday last week.Sterritt pruchased 88,235 at 34

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.